Rank-Heat Plot

A novel way to present the results from a network meta-analysis including multiple outcomes

  • Menu
  • ☰
  • Home
  • Interactive Version
    Ranking Statistics NNT
  • Treatment Ranking
    Ranking Statistics NNT
  • User Guide (PDF)
  • Contact Us

Interactive Rank-heat Plot using Treatment Ranking statistics


Select a Project:


Select Outcomes:


Select your filters

Design your plot by adding labels, asterisks or values for the plot

?
X

Color Palette

"color": the scale consists of the transformation of three colors red (0%), yellow (50%), and green (100%)


"grey": a dark grey corresponds to the smallest ranking value (0%) and a light grey corresponds to the highest ranking value (100%).


?
X

Asterisk Symbol

Indicates whether a sector refers to treatments without data on the outcome within the circle.

Note: If "grey" option was selected from color palette, the only available option is "yes" to avoid confusion between the white cells (highest ranking value (100%)) and the white cells without data.

The asterisk symbol in the plot.


?
X

Show SUCRA values on plot

Indicates whether to show the values of each sector.

"yes"


"no"


?
X

Treatments Labels

Referred to the included treatments across the sectors of circles. Should be one of:

"letters"= for alphabetical characters.


"numbers"= for numerical values.


Rank-heat plot & results

References:
Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, Harrington A, Wilson C, Tsouros S, Soobiah C, Yu CH, Hutton B, Hoch JS, Hemmelgarn BR, Moher D, Majumdar SR, Straus SE. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014 Oct 1;349:g5459 (PMID: 25274009)

Rank-heat plot & results

References:
Tricco AC, Soobiah C, .Blondal E, Veroniki AA, Khan PA, Vafaei A, Ivory J, Strifler L, Ashoor H, MacDonald H, Reynen E, Robson R, Ho J, Ng C, Antony J, Mrklas K, Hutton B, Hemmelgarn B, Moher D, Straus SE. (2015). Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoingsurgery: A systematic review and network meta-analysis. BMC Medicine. 13(136): 13 (PMID: 26084277)

Tricco AC, Soobiah C, .Blondal E, Veroniki AA, Khan PA, Vafaei A, Ivory J, Strifler L, Ashoor H, MacDonald H, Reynen E, Robson R, Ho J, Ng C, Antony J, Mrklas K, Hutton B, Hemmelgarn B, Moher D, Straus SE. (2015). Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: A systematic review and network meta-analysis. BMC Medicine. 13(142): 13 (PMID: 26084332)

Rank-heat plot & results

References:
Tricco AC, Strifler L, .Veroniki A.A., Yazdi F, Khan PA, Scott A., Ng C, Antony J, Mrklas K, D’Souza J, Cardoso R, Straus SE. (2015). Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: A systematic review and network meta-analysis. BMJ Open. 5(12): e010160 (PMID: 26503392)

Rank-heat plot & results

References:
--

Treatments
1 : Detemir[od/bid]
2 : Glargine[od]
3 : Glargine[bid]
4 : Detemir[od]
5 : NPH[od/bid]
6 : Detemir[qid]
7 : NPH[od]
8 : NPH[qid]
Treatments
a : Detemir[od/bid]
b : Glargine[od]
c : Glargine[bid]
d : Detemir[od]
e : NPH[od/bid]
f : Detemir[qid]
g : NPH[od]
h : NPH[qid]
Treatments
1 : Ondansetron + Dexamethasone
2 : Granisetron
3 : Dolasetron + Droperidol IV
4 : Granisetron + Dexamethasone
5 : Ondansetron + Droperidol IV
6 : Ondansetron
7 : Dolasetron
8 : Granisetron + Droperidol IV
9 : Dolasetron + Dexamethasone
10 : Tropisetron
11 : Ramosetron
12 : Palonosetron
13 : Ondansetron + Metoclopramide IV
14 : Palonosetron + Dexamethasone
15 : Placebo
Treatments
a : Ondansetron + Dexamethasone
b : Granisetron
c : Dolasetron + Droperidol IV
d : Granisetron + Dexamethasone
e : Ondansetron + Droperidol IV
f : Ondansetron
g : Dolasetron
h : Granisetron + Droperidol IV
i : Dolasetron + Dexamethasone
j : Tropisetron
k : Ramosetron
l : Palonosetron
m : Ondansetron + Metoclopramide IV
n : Palonosetron + Dexamethasone
o : Placebo
Treatments
1 : INDA/GLYC
2 : GLYC
3 : TIOT
4 : ACLI
5 : BUDE
6 : SALM/FLUT
7 : INDA
8 : FORM
9 : SALM
10 : Placebo
11 : FORM/BUDE
12 : AZD3199
13 : FORM/MOME
14 : BECL/FORM
15 : UMEC
16 : VILA/FLUT
17 : FLUT
18 : INDA/TIOT
19 : VILA/UMEC
20 : TIOT/BUDE/FORM
21 : TIOT/FLUT/SALM
22 : VILA
23 : SALM/TIOT
24 : MOME
25 : FORM/TIOT
26 : TRIAM
27 : TIOT + Resp
28 : GSK961081
29 : FLUT/TIOT
30 : FORM/BUDE/TIOT
Treatments
a : INDA/GLYC
b : GLYC
c : TIOT
d : ACLI
e : BUDE
f : SALM/FLUT
g : INDA
h : FORM
i : SALM
j : Placebo
k : FORM/BUDE
l : AZD3199
m : FORM/MOME
n : BECL/FORM
o : UMEC
p : VILA/FLUT
q : FLUT
r : INDA/TIOT
s : VILA/UMEC
t : TIOT/BUDE/FORM
u : TIOT/FLUT/SALM
v : VILA
w : SALM/TIOT
x : MOME
y : FORM/TIOT
z : TRIAM
za : TIOT + Resp
zb : GSK961081
zc : FLUT/TIOT
zd : FORM/BUDE/TIOT
Treatments
1 : Detemir[od/bid]
2 : Glargine[od]
3 : Glargine[bid]
4 : Detemir[od]
5 : NPH[od/bid]
6 : Detemir[qid]
7 : NPH[od]
8 : NPH[qid]
Treatments
a : Detemir[od/bid]
b : Glargine[od]
c : Glargine[bid]
d : Detemir[od]
e : NPH[od/bid]
f : Detemir[qid]
g : NPH[od]
h : NPH[qid]


209 Victoria Street, 7th Floor, East Building
Toronto, ON, Canada
M5B 1T8